Dr Cicily Scaria

🩸👩🏻‍⚕️🎗️🩺
MDRT RCC

DM MEDICAL ONCOLOGY RESIDENT

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

We want our patients as fit as possible when we transplant them!

If aza+ven can get them there without beating them up, we'd take it 🙌🏽

@COSTEMCongress

[ANI @ANI]

#WATCH |"I had never thought I would get a chance to speak to you, sir," says Flydubai Captain Smit Machchhar to PM Modi.

"You have made the whole country proud," the PM tells the brave Captain.

[Benlazar S M A @smbenlazar]

Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment |American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/YhTPGXLO7j

[Vincent Rajkumar @VincentRK]

Profound sorry that my mentor, friend, and colleague, the legend Bob Kyle passed away. His contributions to patients, medicine, myeloma, @IMFmyeloma @MayoClinic myeloma group, and the institution are monumental. A role model who will be remembered for his integrity and commitment to patients. I owe my career to him. He leaves behind a legacy of experts at Mayo Clinic as well as world over who were influenced greatly by him.

See thread for links to a video an article on him that I wrote for @MayoProceedings

Post your memories below.

[MV Chandrakanth @ChandrakanthMv]

SUPER-SIMPLE 1L mTNBC ALGORITHM | ESMO 2026

How I approach first-line metastatic TNBC when all options are accessible:

PD-L1 → DFI → gBRCA → early relapse → treatment.

The big 2026 shift: ADCs have moved right into the first-line conversation — including pembrolizumab + sacituzumab govitecan for CPS ≥10 with DFI ≥6 months, and Dato-DXd/SG for PD-L1-negative, gBRCA-WT disease.

Simple algorithm. Important caveats. ESMO 2026.

Reference: de Azambuja E, et al. Ann Oncol. 2026;37:1203–1217.

[Benlazar S M A @smbenlazar]

Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management https://t.co/Ci5crFKjq8 #APL

[Vincent Rajkumar @VincentRK]

Celebrating our @NEJM paper that showed that 2 years of lenalidomide maintenance is sufficient in myeloma. A 15 year journey. The results of this trial will in my opinion save over a billion dollars a year for Medicare.

@myelomaMD as the PI worked tirelessly and I’m so fortunate to have him as a dear friend and colleague. @eaonc @theNCI

[Vincent Rajkumar @VincentRK]

Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI

Implications are HUGE. This is a drug we spends billions on each year:

-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD

National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG

https://t.co/k8nGWeSA03

[Vincent Rajkumar @VincentRK]

Human scientific ingenuity and hardwork, not AI. Human clinical trialists and patients, not AI

The standing ovation at #ASCO26 for the unprecedented results in metastatic pancreatic cancer with daraxonrasib an oral RAS inhibitor is the result of research excellence and perseverance, and a witness to this.

AI won’t do the work or run the trials to make these advances. It can make the process easier in the future. But you still need human ingenuity and hard works to take a chemical and make it an effective approved medicine.

Institutions and companies must nurture the human talent. Academic medicine is bleeding talent. Leaders are appointed for pliability over excellence. With NIH funding of new investigators at an all time low, coupled with institutions and organizations extolling the efficiencies and prioritizing the virtues of AI, we are at risk slowing down our ability in drug development.

https://t.co/2YRwESyIuu

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[MV Chandrakanth @ChandrakanthMv]

RASolute-302 delivers a long-awaited breakthrough in metastatic PDAC.

• OS: 13.2 vs 6.7 months
• HR for death: 0.40
• 12-mo OS: 53.2% vs 17.3%
• ORR: 31.6% vs 11.2%

The first Phase III success for broad RAS(ON) inhibition in pancreatic cancer.

O'Reilly et al. #ASCO2026

#PancreaticCancer #PDAC #RAS #Daraxonrasib #MVOnco

[Dr Rishabh Jain @DrRishabhOnco]

Mainstream media may never raise this issue.
But cancer patients across India are paying the price every single day.

No cisplatin. No carboplatin. Delayed chemotherapy. Families waiting helplessly.

If independent voices don’t speak now, who will?

Please repost. Make noise. Force attention.
Because silence is also harmful.

#OncoTwitter #MedTwitter #CisplatinShortage #drugshortage
#NotAllNewsIsNews
@PMOIndia @JPNadda
@newslaundry @TheDeshBhakt @ravish_journo @Cockroachisback @RahulGandhi @theliverdoc

[Veli Bakalov, MD @HemeOncBuddy]

#HemeOncHeroes series. Story #9

In October 1923, a young Indian medical graduate arrived in Boston with $100 to his name, $50 short of Harvard's tuition.

His LMS from Madras Medical College was enough to enter Harvard's School of Tropical Medicine, but not enough for a Massachusetts medical license or an internship.

To survive, he worked nights as a porter at Peter Bent Brigham Hospital, cleaning bedpans and urinals while studying biochemistry.

1/12

pic: 1995 commemorative Indian stamp of Yellapragada SubbaRow.

[Veli Bakalov, MD @HemeOncBuddy]

#HemeOncHeroes series. Story #6

In 1955, childhood leukemia was almost uniformly fatal.

The pediatric leukemia ward at the National Cancer Institute @theNCI carried the smell of antiseptic, transfusions blood, and infection.

🧵 1/14

pic: Emil J Freireich, MD. The hematologist who refused to accept how children with leukemia died.

[Dr Kamlesh Darji @DrKamleshDarji1]

Pressure doesn’t build diamonds in medicine - it builds burnout.
What shapes a doctor is not sleepless nights, but systems that respect limits.
Stop glorifying suffering. Start designing sustainability.

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Patients with aplastic anemia need a transplant, not just red cell/platelet transfusions 🙏🏽

Unfortunately, many patients in the 🇮🇳 subcontinent don't get a transplant despite having sibling donors 😭 That needs to change 🙏🏽

[Vincent Rajkumar @VincentRK]

I’m really proud @BloodCancerJnl is doing so well. We are getting a huge number of high quality submissions. It’s gratifying to take a journal from inception to this level in 15 years.

Our goal is to be #1.
@SagarLonialMD @Mohty_EBMT @n_gangat https://t.co/jtJT7zSTGN

[Sann @san_x_m]

Her name was Asha Bhosle.

She was born in a small village in Sangli in 1933.

Her father died when she was 9. The family had no money. She started singing at 10 to feed her siblings.

At 16 she eloped against her family’s wishes. Her sister Lata stopped speaking to her. Her family disowned her. The marriage was abusive. It ended in 1960.

She came back with two children and pregnant with a third.

No money. No support. Three children to feed.

She went back to singing.

Nobody wanted her. In the 1950s she got only the songs Lata, Geeta Dutt and Shamshad Begum rejected. Songs for vamps. Cabaret numbers. C grade films.

She sang every single one. Because her children needed to eat.

Then came O.P. Nayyar. Then R.D. Burman. Then the world changed.

Dum Maro Dum. Piya Tu Ab To Aaja. Chura Liya Hai Tumne. She did not just sing these songs. She became them.

In 1995 at age 62 she sang Rangeela Re and silenced an entire generation that had written her off.

In 2011 the Guinness Book of World Records confirmed what India already knew. Most recorded artist in music history. 12,000 songs. 20 languages. 8 decades.

She passed away today at 92 in Mumbai.

The girl who sang vamp songs because nobody else would take her became the voice of a generation.

There will never be another Asha Bhosle.

Rest in peace Asha tai.

[Vincent Rajkumar @VincentRK]

Met with the legend Bob Kyle yesterday. He has been our mentor and inspiration.

@myelomaMD @MayoClinic

[Nachiket Bhatia @bhatia_nachiket]

A PG resident at GMC Haldwani reports 24×7 duty for a month straight, with just 1–1.5 hours of sleep per night and no post-call offs.

This isn’t training. This is systemic abuse.

A doctor pushed to the edge of mental breakdown cannot deliver safe care.
Who is accountable if patients suffer?

Healthcare cannot run on sleep-deprived, collapsing doctors.

Authorities must act NOW.

@NMC_IND @MoHFW_INDIA @PMOIndia @DHFWS_UK @ANI @PTI_News

#MedicoLivesMatter #DoctorsOfIndia #ResidentDoctors #MedicalAbuse #GMC #HealthcareCrisis #SaveDoctors #EndExploitation #MedTwitterIndia #RightToRest